登录 注册 会员服务 联系我们

Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016

  • Published:2018-02 Issue:2 Volume:48 Page:165-172
  • ISSN:1444-0903
  • Container-title:Internal Medicine Journal
  • language:en
  • Short-container-title:Intern Med J

Author:

Wongseelashote Sarah1ORCID,Tayal Vipin2,Bourke Peter Francis23

Affiliation:

1. General and Acute Care Medicine; Royal Darwin Hospital; Tiwi Northern Territory Australia

2. Division of Medicine (Rheumatology); Royal Darwin Hospital; Tiwi Northern Territory Australia

3. Division of Integrated Medicine and Emergency Services (Clinical Immunology); Cairns Hospital; Cairns Queensland Australia

Publisher

Wiley

Subject

Internal Medicine

Reference36 articles.

1. Suppression of normal immune responses after treatment with rituximab;Kado;Curr Opin Rheumatol,2016

2. Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia;Yu;BMC Cancer,2010

3. B-cell-directed therapies for autoimmune disease;Dorner;Nat Rev Rheumatol,2009

4. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases;Cooper;Br J Haematol,2010

5. Australian Institute of Health and Welfare http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418551&libID=10737418550
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3